Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the pricing of its initial public offering of 5,333,333 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions, for gross proceeds of approximately $75 million. All of the shares are being offered by Allena. In addition, Allena has granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock at the initial public offering price. The shares are scheduled to begin trading on the NASDAQ Global Select Market under the ticker symbol "ALNA" on Thursday, November 2, 2017. The offering is expected to close on November 6, 2017, subject to the satisfaction of customary closing conditions.

Credit Suisse, Jefferies, and Cowen are acting as the lead book-running managers of the offering. Wedbush PacGrow is acting as the co-manager for the proposed offering.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on November 1, 2017. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at 800-221-1037 or by email at newyork.prospectus@credit-suisse.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 , or by telephone at 877-821-7388; or Cowen and Company, LLC, at c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 631-274-2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannahd@sternir.com